United Therapeutics (NASDAQ:UTHR) was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, December 26th.
Other equities analysts have also recently issued research reports about the stock. TheStreet cut shares of United Therapeutics from a “b-” rating to a “c” rating in a research report on Friday, September 29th. Oppenheimer reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Friday, September 8th. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Cowen reissued a “hold” rating and issued a $129.00 price target on shares of United Therapeutics in a research report on Friday, October 27th. Finally, Zacks Investment Research cut shares of United Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 3rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $138.50.
Shares of United Therapeutics (NASDAQ:UTHR) opened at $141.27 on Tuesday. The stock has a market cap of $6,176.15, a P/E ratio of 12.46 and a beta of 1.41. United Therapeutics has a 1-year low of $112.01 and a 1-year high of $169.89.
United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The firm had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. During the same quarter last year, the firm earned $4.23 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. research analysts forecast that United Therapeutics will post 12.96 earnings per share for the current year.
In related news, CEO Martine A. Rothblatt sold 1,263 shares of the company’s stock in a transaction that occurred on Thursday, October 26th. The shares were sold at an average price of $120.38, for a total transaction of $152,039.94. Following the completion of the transaction, the chief executive officer now owns 1,403 shares of the company’s stock, valued at $168,893.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher Causey sold 580 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $122.00, for a total transaction of $70,760.00. Following the transaction, the director now directly owns 2,135 shares of the company’s stock, valued at approximately $260,470. The disclosure for this sale can be found here. Insiders sold 15,773 shares of company stock worth $1,925,637 in the last ninety days. Insiders own 7.80% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board acquired a new stake in United Therapeutics during the 2nd quarter valued at $5,256,000. River & Mercantile Asset Management LLP acquired a new stake in United Therapeutics during the 2nd quarter valued at $908,000. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in United Therapeutics by 2.3% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 123,016 shares of the biotechnology company’s stock valued at $15,959,000 after purchasing an additional 2,762 shares in the last quarter. Captrust Financial Advisors acquired a new stake in United Therapeutics during the 2nd quarter valued at $925,000. Finally, AXA grew its holdings in United Therapeutics by 1.1% during the 2nd quarter. AXA now owns 95,429 shares of the biotechnology company’s stock valued at $12,380,000 after purchasing an additional 1,000 shares in the last quarter. 99.99% of the stock is owned by institutional investors and hedge funds.
WARNING: “ValuEngine Upgrades United Therapeutics (UTHR) to “Strong-Buy”” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2018/01/14/united-therapeutics-uthr-lifted-to-strong-buy-at-valuengine-updated-updated.html.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.